Anti-CD34 antibody (Clone: QBEND-10)

Cat# NB-22-51756-200

Size : 0.2mg

Richiedere ulteriori informazioni

Contatta il distributore locale :


Telefono : +1 850 650 7790

General Info

Host: Mouse
Applications: IHC-F/IHC-P/WB/FC/IP/IF/EM
Reactivity: Human/Rhesus/Cynomolgus Monkey
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Mouse monoclonal antibody anti-CD34 is suitable for use in Immunohistochemistry, Western Blot, Flow Cytometry, Immunoprecipitation, Immunofluorescence and EM research applications.
Clonality: Monoclonal
Clone ID: QBEND-10
Conjugation: Unconjugated
Isotype: IgG1
Formulation: PBS with 0.09% sodium azide
Concentration: 1.0 mg/mL
Dilution Range: FC 1:100-1:200
IHC 1:500-1:1000
Storage Instruction: Store at 2-8°C upon receipt.

Information

Gene Symbol: CD34
Gene ID: 947
Uniprot ID: CD34_HUMAN
Immunogen: Human endothelial cell membrane vesicles.

Description

Tissue Specificity Selectively expressed on hematopoietic progenitor cells and the small vessel endothelium of a variety of tissues.
Post Translational Modifications Highly glycosylated. Phosphorylated on serine residues by PKC.
Function Possible adhesion molecule with a role in early hematopoiesis by mediating the attachment of stem cells to the bone marrow extracellular matrix or directly to stromal cells. Could act as a scaffold for the attachment of lineage specific glycans, allowing stem cells to bind to lectins expressed by stromal cells or other marrow components. Presents carbohydrate ligands to selectins.
Protein Name Hematopoietic Progenitor Cell Antigen Cd34
Cd Antigen Cd34
Database Links Reactome: R-HSA-198933 P28906-1
Cellular Localisation Membrane
Single-Pass Type I Membrane Protein
Alternative Antibody Names Anti-Hematopoietic Progenitor Cell Antigen Cd34 antibody
Anti-Cd Antigen Cd34 antibody
Anti-CD34 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance